nach oben

Journal of Nephrology

Erschienen in:

01.10.2019 | Review

The role of uric acid in mineral bone disorders in chronic kidney disease

verfasst von: Baris Afsar, Alan A. Sag, Cinar Oztosun, Masanari Kuwabara, Mario Cozzolino, Adrian Covic, Mehmet Kanbay

Erschienen in: Journal of Nephrology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Increasing survival in the chronic kidney disease (CKD) population exposes the bone to the cumulative detrimental sequelae of CKD, now defined physiologically and histopathologically as chronic kidney disease mineral bone disorder (CKD-BMD). This disorder is increasingly recognized as a “nontraditional” driver of morbidity and mortality and presents an opportunity to improve CKD outcomes via research. However, recent advances in the literature on this topic have not yet been collected into a single review. Therefore, this report aims to discuss the disordered renal-bone axis in CKD-BMD, molecular and hormonal drivers, novel treatment strategies, and forthcoming research in a clinician-directed format. A key novel topic will be the unique impact of uric acid on CKD-BMD, which is poised to apply extensive existing research in the uric acid domain to benefit the CKD-BMD population.

Covic A, Kanbay M, Voroneanu L, Turgut F, Serban DN, Serban IL et al (2010) Vascular calcification in chronic kidney disease. Clin Sci (Lond). 119(3):111–121CrossRefPubMed

Sag AA, Covic A, London G, Vervloet M, Goldsmith D, Gorriz JL et al (2016) Clinical imaging of vascular disease in chronic kidney disease. Int Urol Nephrol 48(6):827–837CrossRefPubMed

Kanbay M, Goldsmith D, Akcay A, Covic A (2009) Phosphate—the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif 27(2):220–230CrossRefPubMed

Afsar B, Turkmen K, Covic A, Kanbay M (2014) An update on coronary artery disease and chronic kidney disease. Int J Nephrol 2014:767424CrossRefPubMedPubMedCentral

Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Aydin M, Eryonucu B et al (2010) Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol 5(10):1780–1786CrossRefPubMedPubMedCentral

Kanbay M, Vervloet M, Cozzolino M, Siriopol D, Covic A, Goldsmith D et al (2017) Novel Faces of Fibroblast Growth Factor 23 (FGF23): iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury. Calcif Tissue Int 100(3):217–228CrossRefPubMed

Kanbay M, Solak Y, Siriopol D, Aslan G, Afsar B, Yazici D et al (2016) Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 48(12):2029–2042CrossRefPubMed

Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H et al (2014) Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab 99(10):E1854–E1861CrossRefPubMed

Hruska KA, Sugatani T, Agapova O, Fang Y (2017) The chronic kidney disease—mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone 100:80–86CrossRefPubMedPubMedCentral

10.

Hahn K, Kanbay M, Lanaspa MA, Johnson RJ, Ejaz AA (2017) Serum uric acid and acute kidney injury: a mini review. J Adv Res. 8(5):529–536CrossRefPubMed

11.

Jensen T, Niwa K, Hisatome I, Kanbay M, Andres-Hernando A, Roncal-Jimenez CA et al (2018) Increased serum uric acid over five years is a risk factor for developing fatty liver. Sci Rep. 8(1):11735CrossRefPubMedPubMedCentral

12.

Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C et al (2016) Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med. 29:3–8CrossRefPubMed

13.

Takir M, Kostek O, Ozkok A, Elcioglu OC, Bakan A, Erek A et al (2015) Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med 63(8):924–929CrossRefPubMed

14.

Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E et al (2011) Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 33(4):298–304CrossRefPubMedPubMedCentral

15.

Kanbay M, Siriopol D, Nistor I, Elcioglu OC, Telci O, Takir M et al (2014) Effects of allopurinol on endothelial dysfunction: a meta-analysis. Am J Nephrol 39(4):348–356CrossRefPubMed

16.

Kanbay M, Solak Y, Dogan E, Lanaspa MA, Covic A (2010) Uric acid in hypertension and renal disease: the chicken or the egg? Blood Purif 30(4):288–295CrossRefPubMed

17.

Toyama T, Furuichi K, Shimizu M, Hara A, Iwata Y, Sakai N et al (2015) Relationship between serum uric acid levels and chronic kidney disease in a japanese cohort with normal or mildly reduced kidney function. PLoS One 10(9):e0137449CrossRefPubMedPubMedCentral

18.

Kanbay M, Yilmaz MI, Sonmez A, Solak Y, Saglam M, Cakir E et al (2012) Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol 36(4):324–331CrossRefPubMed

19.

Kanbay M, Ikizek M, Solak Y, Selcoki Y, Uysal S, Armutcu F et al (2011) Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol 33(4):325–331CrossRefPubMedPubMedCentral

20.

von Lueder TG, Girerd N, Atar D, Agewall S, Lamiral Z, Kanbay M et al (2015) Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the high-risk myocardial infarction database initiative. Eur J Heart Fail 17(11):1144–1151CrossRef

21.

Turak O, Ozcan F, Tok D, Isleyen A, Sokmen E, Tasoglu I et al (2013) Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension. J Clin Hypertens (Greenwich). 15(1):7–13CrossRef

22.

Cagli K, Turak O, Canpolat U, Ozcan F, Tok D, Mendi MA et al (2015) Association of serum uric acid level with blood pressure variability in newly diagnosed essential hypertension. J Clin Hypertens (Greenwich). 17(12):929–935CrossRefPubMedCentral

23.

Kuwabara M, Kanbay M, Hisatome I (2018) Uric acid and hypertension because of arterial stiffness. Hypertension 72(3):582–584CrossRefPubMed

24.

Lundquist AL, Nigwekar SU (2016) Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease. Curr Opin Nephrol Hypertens 25(2):120–126CrossRefPubMedPubMedCentral

25.

Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71(1):31–38CrossRefPubMed

26.

Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79(12):1370–1378CrossRefPubMedPubMedCentral

27.

Farrow EG, Davis SI, Summers LJ, White KE (2009) Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20(5):955–960CrossRefPubMedPubMedCentral

28.

Juppner H, Wolf M, Salusky IB (2010) FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res 25(10):2091–2097CrossRefPubMedPubMedCentral

29.

Vervloet MG, Sezer S, Massy ZA, Johansson L, Cozzolino M, Fouque D et al (2017) The role of phosphate in kidney disease. Nat Rev Nephrol. 13(1):27–38CrossRefPubMed

30.

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 69(11):1945–1953CrossRefPubMed

31.

Goodman WG (2005) The evolution of assays for parathyroid hormone. Semin Dial 18(4):296–301CrossRefPubMed

32.

Ferreira A, Drueke TB (2000) Biological markers in the diagnosis of the different forms of renal osteodystrophy. Am J Med Sci 320(2):85–89CrossRefPubMed

33.

Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D’Avino R Jr et al (2018) CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies. Atherosclerosis. 278:49–59CrossRefPubMed

34.

Kanbay M, Afsar B, Gusbeth-Tatomir P, Covic A (2010) Arterial stiffness in dialysis patients: where are we now? Int Urol Nephrol 42(3):741–752CrossRefPubMed

35.

Bikle DD (2014) Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 21(3):319–329CrossRefPubMedPubMedCentral

36.

Peng H, Li H, Li C, Chao X, Zhang Q, Zhang Y (2013) Association between vitamin D insufficiency and elevated serum uric acid among middle-aged and elderly Chinese Han women. PLoS One 8(4):e61159CrossRefPubMedPubMedCentral

37.

Yilmaz H, Kaya M, Sahin M, Delibasi T (2012) Is vitamin D status a predictor glycaemic regulation and cardiac complication in type 2 diabetes mellitus patients? Diabetes Metab Syndr. 6(1):28–31CrossRefPubMed

38.

Vanholder R, Patel S, Hsu CH (1993) Effect of uric acid on plasma levels of 1,25(OH)2D in renal failure. J Am Soc Nephrol 4(4):1035–1038PubMed

39.

Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Yamakita J, Higashino K (1998) Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. Metabolism. 47(3):336–338CrossRefPubMed

40.

Hsu CH, Patel SR, Young EW, Vanholder R (1991) Effects of purine derivatives on calcitriol metabolism in rats. Am J Physiol 260(4 Pt 2):F596–F601PubMed

41.

Chen W, Roncal-Jimenez C, Lanaspa M, Gerard S, Chonchol M, Johnson RJ et al (2014) Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. Metabolism. 63(1):150–160CrossRefPubMed

42.

Thakkinstian A, Anothaisintawee T, Chailurkit L, Ratanachaiwong W, Yamwong S, Sritara P et al (2015) Potential causal associations between vitamin D and uric acid: bidirectional mediation analysis. Sci Rep. 5:14528CrossRefPubMedPubMedCentral

43.

Chin KY, Nirwana SI, Ngah WZ (2015) Significant association between parathyroid hormone and uric acid level in men. Clin Interv Aging 10:1377–1380CrossRefPubMedPubMedCentral

44.

Hui JY, Choi JW, Mount DB, Zhu Y, Zhang Y, Choi HK (2012) The independent association between parathyroid hormone levels and hyperuricemia: a national population study. Arthritis Res Ther. 14(2):R56CrossRefPubMedPubMedCentral

45.

Alemzadeh R, Kichler J (2016) Uric acid-induced inflammation is mediated by the parathyroid hormone: 25-hydroxyvitamin D ratio in obese adolescents. Metab Syndr Relat Disord. 14(3):167–174CrossRefPubMed

46.

Saleh F, Jorde R, Sundsfjord J, Haug E, Figenschau Y (2006) Causes of secondary hyperparathyroidism in a healthy population: the Tromso study. J Bone Miner Metab 24(1):58–64CrossRefPubMed

47.

Hisatome I, Ishimura M, Sasaki N, Yamakawa M, Kosaka H, Tanaka Y et al (1992) Renal handling of urate in two patients with hyperuricemia and primary hyperparathyroidism. Intern Med 31(6):807–811CrossRefPubMed

48.

Westerdahl J, Valdemarsson S, Lindblom P, Bergenfelz A (2001) Urate and arteriosclerosis in primary hyperparathyroidism. Clin Endocrinol (Oxf) 54(6):805–811CrossRef

49.

Bergenfelz A, Bladstrom A, Their M, Nordenstrom E, Valdemarsson S, Westerdahl J (2007) Serum levels of uric acid and diabetes mellitus influence survival after surgery for primary hyperparathyroidism: a prospective cohort study. World J Surg. 31(7):1393–1400 (discussion 401-2) CrossRefPubMed

50.

Valdemarsson S, Lindblom P, Bergenfelz A (1998) Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J Intern Med 244(3):241–249CrossRefPubMed

51.

Christensson T (1977) Serum urate in subjects with hypercalcaemic hyperparathyroidism. Clin Chim Acta 80(3):529–533CrossRefPubMed

52.

Dalbeth N, Horne A, Gamble GD, Ames R, Mason B, McQueen FM et al (2009) The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. Rheumatology (Oxford) 48(2):195–197CrossRef

53.

Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18(1):59–68CrossRefPubMed

54.

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19(3):429–435CrossRefPubMed

55.

Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64(6):2272–2279CrossRefPubMed

56.

Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 205(2):385–390CrossRefPubMed

57.

Sakoh T, Nakayama M, Tsuchihashi T, Yoshitomi R, Tanaka S, Katafuchi E et al (2016) Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease. Metabolism. 65(10):1498–1507CrossRefPubMed

58.

Asicioglu E, Kahveci A, Arikan H, Koc M, Tuglular S, Ozener C (2014) Fibroblast growth factor-23 levels are associated with uric acid but not carotid intima media thickness in renal transplant recipients. Transplant Proc. 46(1):180–183CrossRefPubMed

59.

Gutierrez OM, Wolf M, Taylor EN (2011) Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 6(12):2871–2878CrossRefPubMedPubMedCentral

60.

Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21(9):1427–1435CrossRefPubMed

61.

Andres M, Quintanilla MA, Sivera F, Sanchez-Paya J, Pascual E, Vela P et al (2016) Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study. Arthritis Rheumatol. 68(6):1531–1539CrossRefPubMed

62.

Kim H, Kim SH, Choi AR, Kim S, Choi HY, Kim HJ et al (2017) Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: a single-center cross-sectional study. Medicine (Baltimore). 96(14):e6565CrossRefPubMedPubMedCentral

63.

Mehta T, Nuccio E, McFann K, Madero M, Sarnak MJ, Jalal D (2015) Association of uric acid with vascular stiffness in the framingham heart study. Am J Hypertens 28(7):877–883CrossRefPubMed

64.

Lee CT, Chua S, Hsu CY, Tsai YC, Ng HY, Kuo CC et al (2013) Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients. Dis Markers 34(4):229–235CrossRefPubMedPubMedCentral

65.

Andrews ES, Perrenoud L, Nowak KL, You Z, Pasch A, Chonchol M et al (2018) Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post hoc analysis of a randomized clinical trial. PLoS One 13(10):e0205831CrossRefPubMedPubMedCentral

66.

Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N et al (2007) Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 39(4):1227–1233CrossRefPubMed

67.

Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388–1393CrossRefPubMedPubMedCentral

68.

Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I et al (2011) A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 6(8):1887–1894CrossRefPubMedPubMedCentral

69.

Nabipour I, Sambrook PN, Blyth FM, Janu MR, Waite LM, Naganathan V et al (2011) Serum uric acid is associated with bone health in older men: a cross-sectional population-based study. J Bone Miner Res 26(5):955–964CrossRefPubMed

70.

Ahn SH, Lee SH, Kim BJ, Lim KH, Bae SJ, Kim EH et al (2013) Higher serum uric acid is associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in healthy postmenopausal women. Osteoporos Int 24(12):2961–2970CrossRefPubMed

71.

Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y (2009) Oxidative stress in bone remodelling and disease. Trends Mol Med. 15(10):468–477CrossRefPubMed

72.

Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS et al (2005) A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106(3):852–859CrossRefPubMed

73.

Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P et al (2003) Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 88(4):1523–1527CrossRefPubMed

74.

Makovey J, Macara M, Chen JS, Hayward CS, March L, Seibel MJ et al (2013) Serum uric acid plays a protective role for bone loss in peri- and postmenopausal women: a longitudinal study. Bone 52(1):400–406CrossRefPubMed

75.

Kim BJ, Baek S, Ahn SH, Kim SH, Jo MW, Bae SJ et al (2014) Higher serum uric acid as a protective factor against incident osteoporotic fractures in Korean men: a longitudinal study using the National Claim Registry. Osteoporos Int 25(7):1837–1844CrossRefPubMed

76.

Zhao DD, Jiao PL, Yu JJ, Wang XJ, Zhao L, Xuan Y et al (2016) Higher serum uric acid is associated with higher bone mineral density in Chinese men with type 2 diabetes mellitus. Int J Endocrinol. 2016:2528956CrossRefPubMedPubMedCentral

77.

Chen Z, Ding Z, Fu C, Yu C, Ma G (2014) Correlation between serum uric Acid and renal function in patients with stable coronary artery disease and type 2 diabetes. J Clin Med Res. 6(6):443–450PubMedPubMedCentral

78.

Kamei K, Konta T, Hirayama A, Suzuki K, Ichikawa K, Fujimoto S et al (2014) A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant 29(12):2286–2292CrossRefPubMed

79.

Malmgren L, McGuigan F, Christensson A, Akesson KE (2017) Reduced kidney function is associated with BMD, bone loss and markers of mineral homeostasis in older women: a 10-year longitudinal study. Osteoporos Int 28(12):3463–3473CrossRefPubMedPubMedCentral

80.

Zhang D, Bobulescu IA, Maalouf NM, Adams-Huet B, Poindexter J, Park S et al (2015) Relationship between serum uric Acid and bone mineral density in the general population and in rats with experimental hyperuricemia. J Bone Miner Res 30(6):992–999CrossRefPubMed

81.

Nybo M, Jespersen B, Aarup M, Ejersted C, Hermann AP, Brixen K (2013) Determinants of bone mineral density in patients on haemodialysis or peritoneal dialysis—a cross-sectional, longitudinal study. Biochem Med (Zagreb). 23(3):342–350CrossRefPubMedPubMedCentral

82.

Denburg MR, Tsampalieros AK, de Boer IH, Shults J, Kalkwarf HJ, Zemel BS et al (2013) Mineral metabolism and cortical volumetric bone mineral density in childhood chronic kidney disease. J Clin Endocrinol Metab 98(5):1930–1938CrossRefPubMedPubMedCentral

83.

Park SH, Jia T, Qureshi AR, Barany P, Heimburger O, Larsson TE et al (2013) Determinants and survival implications of low bone mineral density in end-stage renal disease patients. J Nephrol. 26(3):485–494CrossRefPubMed

84.

Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Kanbay M, Ortiz A. Potential dangers of serum urate-lowering therapy. Am J Med. 2019

85.

Barreto FC, Costa C, Reis LMD, Custodio MR. Bone biopsy in nephrology practice. J Bras Nefrol. 2018

86.

Cheng Q, Wu X, Du Y, Hong W, Tang W, Li H et al (2018) Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol. Clin Interv Aging 13:2367–2374CrossRefPubMedPubMedCentral

87.

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297CrossRefPubMed

88.

Grieco GE, Cataldo D, Ceccarelli E, Nigi L, Catalano G, Brusco N et al (2018) Serum levels of miR-148a and miR-21-5p are increased in Type 1 diabetic patients and correlated with markers of bone strength and metabolism. Noncoding RNA. 4(4):37PubMedCentral

89.

Yao CJ, Lv Y, Zhang CJ, Jin JX, Xu LH, Jiang J et al (2018) MicroRNA-185 inhibits the growth and proliferation of osteoblasts in fracture healing by targeting PTH gene through down-regulating Wnt/beta-catenin axis: in an animal experiment. Biochem Biophys Res Commun 501(1):55–63CrossRefPubMed

90.

Shilo V, Mor-Yosef Levi I, Abel R, Mihailovic A, Wasserman G, Naveh-Many T et al (2017) Let-7 and MicroRNA-148 regulate parathyroid hormone levels in secondary hyperparathyroidism. J Am Soc Nephrol 28(8):2353–2363CrossRefPubMedPubMedCentral

91.

Jeong S, Oh JM, Oh KH, Kim IW (2017) Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients. PLoS One 12(2):e0170535CrossRefPubMedPubMedCentral

92.

Shao Y, Ren H, Lv C, Ma X, Wu C, Wang Q (2017) Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease. Endocrine 55(1):130–138CrossRefPubMed

93.

Tang ZM, Fang M, Wang JP, Cai PC, Wang P, Hu LH (2014) Clinical relevance of plasma miR-21 in new-onset systemic lupus erythematosus patients. J Clin Lab Anal 28(6):446–451CrossRefPubMedPubMedCentral

94.

Hong Q, Yu S, Geng X, Duan L, Zheng W, Fan M et al (2015) High concentrations of uric acid inhibit endothelial cell migration via miR-663 which regulates phosphatase and tensin homolog by targeting transforming growth factor-beta1. Microcirculation. 22(4):306–314CrossRefPubMed

95.

Yu S, Hong Q, Wang Y, Hou K, Wang L, Zhang Y et al (2015) High concentrations of uric acid inhibit angiogenesis via regulation of the Kruppel-like factor 2-vascular endothelial growth factor-A axis by miR-92a. Circ J 79(11):2487–2498CrossRefPubMed

96.

Evenepoel P, D’Haese P, Brandenburg V (2015) Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 88(2):235–240CrossRefPubMed

97.

Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC et al (2014) CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol 25(8):1760–1773CrossRefPubMedPubMedCentral

98.

Sugatani T, Agapova OA, Fang Y, Berman AG, Wallace JM, Malluche HH et al (2017) Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. Kidney Int 91(1):86–95CrossRefPubMed

99.

Sugatani T (2018) Systemic activation of activin a signaling causes chronic kidney disease-mineral bone disorder. Int J Mol Sci. 19(9):2490CrossRefPubMedCentral

100.

Peng LN, Chou MY, Liang CK, Lee WJ, Kojima T, Lin MH et al (2018) Association between serum activin A and metabolic syndrome in older adults: potential of activin A as a biomarker of cardiometabolic disease. Exp Gerontol 111:197–202CrossRefPubMed

Titel: The role of uric acid in mineral bone disorders in chronic kidney disease
verfasst von: Baris Afsar
Alan A. Sag
Cinar Oztosun
Masanari Kuwabara
Mario Cozzolino
Adrian Covic
Mehmet Kanbay
Publikationsdatum: 01.10.2019
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 5/2019
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-019-00615-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The role of uric acid in mineral bone disorders in chronic kidney disease

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis

Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis

Catheter-related infections in peritoneal dialysis: comparison of a single center results and the literature data

When kidneys and lungs suffer together

Updates on urinary tract infections in kidney transplantation

Homocysteine and chronic kidney disease: an ongoing narrative

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin